9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder

Author's Avatar
Mar 02, 2022

RALEIGH, NC / ACCESSWIRE / March 2, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today a collaboration with NYU Langone Health investigating the pre-clinical use of 9 Meters' gut-restricted tight junction regulator, NM-102, for an undisclosed autoimmune condition with a large unmet need.